Advisory board · Dr. Chloé Dubois

• Brain-metastasis subgroup data
• Chemotherapy-free first line
• Duration of response

• VTX core scientific deck v3.2
• VOYAGE-1 pivotal data summary

1. What is the evidence for re-challenge with checkpoint inhibitors after progression on vantrelimab?
2. What was the median PD-L1 testing turnaround in the pivotal trial sites?

Advisory board with oncology pharmacist at Vall d'Hebron. Discussed brain-metastasis subgroup data, chemotherapy-free first line, duration of response.